Previously, it was shown that PKM2 knockdown in the PKM2-overexpressed prostate cancer cell line DU145 induced autophagic cell death by influencing cellular metabolism and the Akt/mTOR pathway [17]; however, PKM2 knockdown therapy is severely limited in clinical treatment. This evidence concerns the gene AKT1 and prostate cancer.